230 related articles for article (PubMed ID: 28218273)
41. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
[TBL] [Abstract][Full Text] [Related]
42. Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.
Anandan SK; Gless RD
Bioorg Med Chem Lett; 2010 May; 20(9):2740-4. PubMed ID: 20363133
[TBL] [Abstract][Full Text] [Related]
43. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids.
Gomez GA; Morisseau C; Hammock BD; Christianson DW
Protein Sci; 2006 Jan; 15(1):58-64. PubMed ID: 16322563
[TBL] [Abstract][Full Text] [Related]
44. Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.
Kim IH; Lee IH; Nishiwaki H; Hammock BD; Nishi K
Bioorg Med Chem; 2014 Feb; 22(3):1163-75. PubMed ID: 24433964
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and biological activity of 4-substituted benzoxazolone derivatives as a new class of sEH inhibitors with high anti-inflammatory activity in vivo.
Tang L; Ma WH; Ma YL; Ban SR; Feng XE; Li QS
Bioorg Med Chem Lett; 2013 Apr; 23(8):2380-3. PubMed ID: 23489630
[TBL] [Abstract][Full Text] [Related]
47. The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat.
Piotrowski J; Jędrzejewski T; Pawlikowska M; Pacuła AJ; Ścianowski J; Kozak W
J Physiol Biochem; 2017 Nov; 73(4):551-560. PubMed ID: 28741242
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.
Morisseau C; Pakhomova S; Hwang SH; Newcomer ME; Hammock BD
Bioorg Med Chem Lett; 2013 Jul; 23(13):3818-21. PubMed ID: 23684894
[TBL] [Abstract][Full Text] [Related]
50. Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.
Pecic S; Zeki AA; Xu X; Jin GY; Zhang S; Kodani S; Halim M; Morisseau C; Hammock BD; Deng SX
Prostaglandins Other Lipid Mediat; 2018 May; 136():90-95. PubMed ID: 29567338
[TBL] [Abstract][Full Text] [Related]
51. Impact of Arachidonic Acid and the Leukotriene Signaling Pathway on Vasculogenesis of Mouse Embryonic Stem Cells.
Huang YH; Sharifpanah F; Becker S; Wartenberg M; Sauer H
Cells Tissues Organs; 2016; 201(5):319-32. PubMed ID: 27198524
[TBL] [Abstract][Full Text] [Related]
52. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.
De Simone R; Chini MG; Bruno I; Riccio R; Mueller D; Werz O; Bifulco G
J Med Chem; 2011 Mar; 54(6):1565-75. PubMed ID: 21323313
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
54. Quinazoline-4(3
Turanlı S; Ergül AG; Jordan PM; Olğaç A; Çalışkan B; Werz O; Banoglu E
ACS Omega; 2022 Oct; 7(41):36354-36365. PubMed ID: 36278102
[TBL] [Abstract][Full Text] [Related]
55. Soluble epoxide hydrolase inhibitory and anti-inflammatory components from the leaves of Eucommia ulmoides Oliver (duzhong).
Bai MM; Shi W; Tian JM; Lei M; Kim JH; Sun YN; Kim YH; Gao JM
J Agric Food Chem; 2015 Mar; 63(8):2198-205. PubMed ID: 25679330
[TBL] [Abstract][Full Text] [Related]
56. Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase.
Hiesinger K; Kramer JS; Beyer S; Eckes T; Brunst S; Flauaus C; Wittmann SK; Weizel L; Kaiser A; Kretschmer SBM; George S; Angioni C; Heering J; Geisslinger G; Schubert-Zsilavecz M; Schmidtko A; Pogoryelov D; Pfeilschifter J; Hofmann B; Steinhilber D; Schwalm S; Proschak E
J Med Chem; 2020 Oct; 63(20):11498-11521. PubMed ID: 33044073
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
[TBL] [Abstract][Full Text] [Related]
59. Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.
Zarriello S; Tuazon JP; Corey S; Schimmel S; Rajani M; Gorsky A; Incontri D; Hammock BD; Borlongan CV
Prog Neurobiol; 2019 Jan; 172():23-39. PubMed ID: 30447256
[TBL] [Abstract][Full Text] [Related]
60. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.
Smith KR; Pinkerton KE; Watanabe T; Pedersen TL; Ma SJ; Hammock BD
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2186-91. PubMed ID: 15684051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
